RecruitingPhase 2NCT07082686
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Intervention
- ICP-248(drug)
- Enrollment
- 75 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (29)
- The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- West China Hospital of Sichuan University, Chengdu, Chengdu, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
- Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Henan Provincial People's Hospital, Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
- Hunan Cancer Hospital, Changsha, Hunan, China
- The First Affiliated Hospital of University of South China, Hengyang, Hunan, China
- +14 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07082686 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06675123Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRuijin Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University
- RECRUITINGPHASE3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)BeOne Medicines